Haystack MRD™ prioritizes truncal somatic mutations—those mutations that are present at the initial formation of a tumor, or the trunk of the cancer evolutionary tree.

One of the most critical differentiators among minimal residual disease (MRD) tests is whether they are tumor-informed or whether they are tumor-naive.

The landmark DYNAMIC study is the first prospective, randomized, interventional trial to demonstrate the clinical benefit of MRD testing to guide adjuvant therapy